Editorial: secondary dyslipidemias.
作者信息
Elisaf Moses, Tsimihodimos Vasilis
机构信息
Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
出版信息
Open Cardiovasc Med J. 2011;5:22-3. doi: 10.2174/1874192401105010022. Epub 2011 Feb 24.
Abstract
摘要
相似文献
1
Editorial: secondary dyslipidemias.社论：继发性血脂异常
Open Cardiovasc Med J. 2011;5:22-3. doi: 10.2174/1874192401105010022. Epub 2011 Feb 24.
2
[Secondary dyslipidemias].[继发性血脂异常]
Vnitr Lek. 2012 Mar;58(3):221-7.
3
[Secondary dyslipidemias and their treatment].[继发性血脂异常及其治疗]
Vnitr Lek. 2007 Apr;53(4):396-400.
4
Secondary causes of dyslipidemia.血脂异常的继发原因。
Am J Cardiol. 2012 Sep 15;110(6):823-5. doi: 10.1016/j.amjcard.2012.04.062. Epub 2012 Jun 2.
5
Editorial: Treatment for NASH - helping the liver or helping the heart?社论：非酒精性脂肪性肝炎的治疗——是有助于肝脏还是有助于心脏？
Aliment Pharmacol Ther. 2015 Mar;41(5):487. doi: 10.1111/apt.13060.
6
Update on the molecular biology of dyslipidemias.血脂异常的分子生物学进展
Clin Chim Acta. 2016 Feb 15;454:143-85. doi: 10.1016/j.cca.2015.10.033. Epub 2015 Nov 4.
7
Editorial: The Different Facets of Diabetes, Dyslipidemia and Hypertension in Cardio-metabolic Diseases: Current Perspective and Future Developments.社论：心血管代谢疾病中糖尿病、血脂异常和高血压的不同方面：当前观点与未来发展
Curr Pharm Des. 2017;23(10):1425-1426. doi: 10.2174/138161282310170512174010.
8
Editorial: the changing face of metabolic syndrome and its components in the light of current knowledge.社论：基于当前知识视角下代谢综合征及其组成部分不断变化的面貌
Curr Vasc Pharmacol. 2014;12(4):549-52. doi: 10.2174/157016111204140702101134.
9
Lipid apheresis - last resort or selective therapeutic option? Proceedings of a symposium held in Bad Oeynhausen, Germany, October 7 - 8, 2011. Editorial.血脂分离术——最后的手段还是选择性治疗方案？2011年10月7日至8日于德国巴特奥伊瑙森举办的一场研讨会会议记录。社论
Clin Res Cardiol Suppl. 2012 Jun;7(Suppl 1):1. doi: 10.1007/s11789-012-0050-x.
10
Editorial: collecting new external evidence for cholesterol management.社论：收集胆固醇管理的新外部证据
Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):121-3. doi: 10.1097/MED.0000000000000244.
引用本文的文献
1
When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson.当低密度脂蛋白胆固醇并非真正的低密度脂蛋白胆固醇时：脂蛋白X，一则临床经验教训。
JACC Case Rep. 2022 Jun 1;4(11):690-693. doi: 10.1016/j.jaccas.2022.03.009.
2
High prevalence of dyslipidemia among primary care patients with hypertension and diabetes in Jamaica.牙买加高血压和糖尿病初级保健患者中血脂异常的高患病率。
Arch Med Sci Atheroscler Dis. 2017 Oct 5;2:e61-e67. doi: 10.5114/amsad.2017.70596. eCollection 2017.
本文引用的文献
1
Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.与贝特类药物治疗相关的横纹肌溶解症：76 例已发表病例的回顾分析及 1 例新病例报告。
Eur J Clin Pharmacol. 2009 Dec;65(12):1169-74. doi: 10.1007/s00228-009-0723-7. Epub 2009 Sep 16.
2
Hypertriglyceridemic pancreatitis: presentation and management.高甘油三酯血症性胰腺炎：临床表现与管理
Am J Gastroenterol. 2009 Apr;104(4):984-91. doi: 10.1038/ajg.2009.27. Epub 2009 Mar 17.
3
Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.慢性肾脏病中的血脂异常：发病机制与治疗方法
Am J Nephrol. 2008;28(6):958-73. doi: 10.1159/000144024. Epub 2008 Jul 9.
4
Lipid changes and statins in chronic renal insufficiency.慢性肾功能不全中的脂质变化与他汀类药物
J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S226-30. doi: 10.1681/ASN.2006080919.
5
A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism.一例因他汀类药物与贝特类衍生物联用及隐匿性甲状腺功能减退继发横纹肌溶解症所致急性肾衰竭。
Clin Nephrol. 2005 Nov;64(5):391-3. doi: 10.5414/cnp64391.
6
Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.服用降血脂药物后出现的显著脂质变化可能揭示亚临床甲状腺功能亢进。
Diabetes Obes Metab. 2001 Apr;3(2):97-8. doi: 10.1046/j.1463-1326.2001.00133.x.
7
Diabetic dyslipidemia.糖尿病血脂异常
Am J Med. 1994 Jun 6;96(6A):25S-31S. doi: 10.1016/0002-9343(94)90228-3.
Zotero 插件